John H Sampson Selected Research

transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38)

1/2005	Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study.
10/2003	Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John H Sampson Research Topics

Disease

147	Neoplasms (Cancer) 01/2023 - 01/2002
94	Glioblastoma (Glioblastoma Multiforme) 01/2023 - 06/2002
69	Glioma (Gliomas) 10/2020 - 02/2002
40	Brain Neoplasms (Brain Tumor) 01/2022 - 11/2002
11	Lymphopenia (Lymphocytopenia) 01/2021 - 02/2008
8	Melanoma (Melanoma, Malignant) 01/2022 - 01/2002
6	Bites and Stings (Sting) 06/2015 - 07/2011
6	Breast Neoplasms (Breast Cancer) 05/2013 - 02/2002
5	Infections 01/2019 - 02/2008
4	Neoplasm Metastasis (Metastasis) 07/2013 - 07/2004
3	Headache (Headaches) 10/2017 - 08/2008
3	Residual Neoplasm 01/2014 - 05/2003
3	Hypersensitivity (Allergy) 03/2011 - 08/2009
2	Surgical Wound Infection 09/2023 - 02/2013
2	Hypoxia (Hypoxemia) 01/2021 - 04/2011
2	Poliomyelitis (Polio) 01/2021 - 11/2014
2	Inflammation (Inflammations) 12/2018 - 11/2015
2	Tetanus 01/2018 - 03/2015
2	Fatigue 10/2017 - 07/2012
2	Medulloblastoma 02/2016 - 10/2015
2	Dizziness (Lightheadedness) 04/2015 - 08/2008
2	Meningioma (Meningiomas) 10/2013 - 01/2012
2	Prostatic Neoplasms (Prostate Cancer) 06/2013 - 01/2011
2	Carcinogenesis 12/2012 - 09/2011
2	Diarrhea 07/2012 - 01/2004
2	Paraganglioma (Paragangliomas) 07/2010 - 06/2009

Drug/Important Bio-Agent (IBA)

40	epidermal growth factor receptor VIIIIBA 01/2023 - 01/2002
36	VaccinesIBA 01/2022 - 02/2002
33	Temozolomide (Temodar)FDA LinkGeneric 01/2022 - 02/2003
33	ErbB Receptors (EGF Receptor)IBA 01/2020 - 01/2002
31	AntigensIBA 01/2023 - 01/2002
14	Peptides (Polypeptides)IBA 01/2022 - 01/2002
12	Monoclonal AntibodiesIBA 02/2016 - 03/2002
11	Bevacizumab (Avastin)FDA Link 01/2020 - 07/2010
10	Chimeric Antigen ReceptorsIBA 01/2023 - 01/2014
8	Immune Checkpoint InhibitorsIBA 10/2022 - 09/2015
8	EpitopesIBA 01/2022 - 10/2008
8	Irinotecan (Camptosar)FDA LinkGeneric 04/2019 - 04/2004
8	Neoplasm Antigens (Tumor Antigens)IBA 01/2019 - 05/2003
7	Protein Subunit VaccinesIBA 01/2018 - 02/2008
7	Immunotoxins (Immunotoxin)IBA 09/2011 - 01/2005
7	IL13-PE38IBA 01/2011 - 04/2006
6	rindopepimutIBA 01/2020 - 03/2013
6	EnzymesIBA 01/2019 - 02/2006
6	RNA (Ribonucleic Acid)IBA 01/2017 - 11/2013
6	Tyrosine Kinase InhibitorsIBA 07/2012 - 11/2002
6	Cytotoxins (Cytolysins)IBA 01/2012 - 04/2006
6	O(6)-benzylguanineIBA 10/2009 - 05/2002
5	Proteins (Proteins, Gene)FDA Link 01/2020 - 05/2003
5	CytokinesIBA 11/2013 - 03/2006
4	AntibodiesIBA 01/2022 - 08/2014
4	keyhole-limpet hemocyanin (keyhole limpet hemocyanin)IBA 01/2020 - 01/2002
4	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2013 - 11/2002
4	Human Serum Albumin FDA LinkGeneric 09/2011 - 02/2007
4	Gefitinib (Iressa)FDA Link 02/2006 - 11/2002
3	NivolumabIBA 01/2022 - 09/2015
3	Cancer VaccinesIBA 01/2022 - 12/2012
3	Interleukin-2 (IL2)IBA 01/2019 - 01/2012
3	poliovirus receptorIBA 12/2018 - 07/2004
3	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 10/2017 - 04/2015
3	Bispecific AntibodiesIBA 06/2015 - 07/2011
3	Granzymes (Granzyme)IBA 12/2014 - 09/2013
3	Trastuzumab (Herceptin)FDA Link 05/2013 - 11/2003
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 03/2013 - 02/2006
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 07/2012 - 06/2002
3	Imatinib Mesylate (Gleevec)FDA Link 01/2012 - 12/2005
3	Hydroxyurea (Hydrea)FDA LinkGeneric 01/2012 - 12/2005
3	DNA (Deoxyribonucleic Acid)IBA 05/2008 - 01/2007
3	ExotoxinsIBA 11/2007 - 10/2003
3	Carmustine (FIVB)FDA Link 04/2004 - 05/2002
2	Anti-Bacterial Agents (Antibiotics)IBA 09/2023 - 08/2008
2	Gadolinium DTPA (Magnevist)FDA Link 01/2023 - 09/2011
2	Therapeutic UsesIBA 01/2022 - 08/2009
2	Tryptophan (L-Tryptophan)FDA Link 01/2021 - 06/2017
2	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2020 - 08/2008
2	Epidermal Growth Factor (EGF)IBA 01/2020 - 01/2008
2	Immunoglobulin FragmentsIBA 01/2020 - 08/2014
2	A-factor (Streptomyces)IBA 01/2019 - 02/2013
2	IpilimumabIBA 01/2018 - 09/2015
2	Transforming Growth Factors (Transforming Growth Factor)IBA 06/2017 - 10/2003
2	Indicators and Reagents (Reagents)IBA 06/2017 - 02/2002
2	Freund's AdjuvantIBA 01/2017 - 09/2003
2	Messenger RNA (mRNA)IBA 01/2017 - 12/2006
2	Viral ProteinsIBA 03/2015 - 05/2014
2	SteroidsIBA 10/2013 - 01/2005
2	Angiogenesis InhibitorsIBA 06/2012 - 04/2011
2	Carboplatin (JM8)FDA LinkGeneric 03/2012 - 12/2011
2	Recombinant Fusion ProteinsIBA 01/2012 - 10/2003
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2011 - 07/2010
2	poliferprosan 20 drug combination carmustine (Gliadel)FDA Link 01/2011 - 02/2009
2	Sirolimus (Rapamycin)FDA Link 01/2010 - 02/2006

Therapy/Procedure

76	Immunotherapy 01/2023 - 02/2002
74	Therapeutics 10/2020 - 11/2002
26	Drug Therapy (Chemotherapy) 01/2021 - 01/2004
16	Radiotherapy 01/2022 - 02/2006
6	Catheters 12/2018 - 02/2007
2	Neurosurgical Procedures 09/2023 - 08/2014
2	Aftercare (After-Treatment) 10/2017 - 05/2004
2	Induction Chemotherapy 10/2015 - 01/2014
2	Chemoradiotherapy 01/2011 - 11/2007